Statistically significant higher DCBLD1 in tumor tissue was observed for all four cancers with median of 1.47 fold for NSCLC, 1.54 fold for invasive breast carcinoma, 1.39 fold for colorectal adenocarcinoma and 1.25 fold for prostate adenocarcinoma. Here, DCBLD1 is linked to prostate adenocarcinoma.